ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.47 Million SEK | 12.5% |
| 2022 | 72.42 Million SEK | 9.42% |
| 2021 | 66.18 Million SEK | -14.23% |
| 2020 | 77.16 Million SEK | 8.68% |
| 2019 | 70.99 Million SEK | 2.62% |
| 2018 | 69.18 Million SEK | 4.63% |
| 2017 | 66.12 Million SEK | 4.16% |
| 2016 | 63.48 Million SEK | 10.43% |
| 2015 | 57.49 Million SEK | 32.38% |
| 2014 | 43.42 Million SEK | -19.26% |
| 2013 | 53.78 Million SEK | 82.95% |
| 2012 | 29.4 Million SEK | 20.46% |
| 2011 | 24.4 Million SEK | 25.38% |
| 2010 | 19.46 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 78 Million SEK | -4.26% |
| 2023 Q3 | 68.49 Million SEK | -3.54% |
| 2023 FY | 81.47 Million SEK | 12.5% |
| 2023 Q1 | 71.91 Million SEK | -0.7% |
| 2023 Q4 | 81.47 Million SEK | 18.94% |
| 2023 Q2 | 71.01 Million SEK | -1.25% |
| 2022 Q1 | 64.64 Million SEK | -2.33% |
| 2022 Q2 | 70.28 Million SEK | 8.72% |
| 2022 FY | 72.42 Million SEK | 9.42% |
| 2022 Q3 | 67.46 Million SEK | -4.0% |
| 2022 Q4 | 72.42 Million SEK | 7.35% |
| 2021 Q3 | 67.95 Million SEK | -0.69% |
| 2021 Q4 | 66.18 Million SEK | -2.6% |
| 2021 FY | 66.18 Million SEK | -14.23% |
| 2021 Q1 | 70.72 Million SEK | -8.34% |
| 2021 Q2 | 68.42 Million SEK | -3.25% |
| 2020 Q2 | 75.46 Million SEK | 2.45% |
| 2020 FY | 77.16 Million SEK | 8.68% |
| 2020 Q1 | 73.66 Million SEK | 3.75% |
| 2020 Q4 | 77.16 Million SEK | 3.75% |
| 2020 Q3 | 74.37 Million SEK | -1.44% |
| 2019 Q3 | 74.58 Million SEK | -0.25% |
| 2019 FY | 70.99 Million SEK | 2.62% |
| 2019 Q4 | 70.99 Million SEK | -4.81% |
| 2019 Q2 | 74.76 Million SEK | -9.18% |
| 2019 Q1 | 82.32 Million SEK | 18.99% |
| 2018 Q1 | 59.27 Million SEK | -10.36% |
| 2018 FY | 69.18 Million SEK | 4.63% |
| 2018 Q4 | 69.18 Million SEK | 12.79% |
| 2018 Q3 | 61.33 Million SEK | 6.41% |
| 2018 Q2 | 57.64 Million SEK | -2.75% |
| 2017 Q1 | 58.38 Million SEK | -8.03% |
| 2017 Q4 | 66.12 Million SEK | -0.91% |
| 2017 Q3 | 66.73 Million SEK | -1.97% |
| 2017 Q2 | 68.07 Million SEK | 16.58% |
| 2017 FY | 66.12 Million SEK | 4.16% |
| 2016 Q4 | 63.48 Million SEK | -3.59% |
| 2016 Q2 | 69.24 Million SEK | 34.22% |
| 2016 Q3 | 65.85 Million SEK | -4.89% |
| 2016 Q1 | 51.59 Million SEK | -10.26% |
| 2016 FY | 63.48 Million SEK | 10.43% |
| 2015 Q2 | 53.73 Million SEK | -1.93% |
| 2015 Q4 | 57.49 Million SEK | 4.94% |
| 2015 Q3 | 54.78 Million SEK | 1.95% |
| 2015 FY | 57.49 Million SEK | 32.38% |
| 2015 Q1 | 54.79 Million SEK | 26.16% |
| 2014 FY | 43.42 Million SEK | -19.26% |
| 2014 Q3 | 44.29 Million SEK | 3.16% |
| 2014 Q2 | 42.93 Million SEK | -7.39% |
| 2014 Q1 | 46.36 Million SEK | -13.81% |
| 2014 Q4 | 43.42 Million SEK | -1.94% |
| 2013 Q4 | 53.78 Million SEK | 41.74% |
| 2013 FY | 53.78 Million SEK | 82.95% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 Q3 | 37.94 Million SEK | 0.0% |
| 2012 Q4 | 29.4 Million SEK | 0.0% |
| 2012 FY | 29.4 Million SEK | 20.46% |
| 2011 FY | 24.4 Million SEK | 25.38% |
| 2010 FY | 19.46 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -29.561% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.522% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.522% |
| Arcoma AB | 81.96 Million SEK | 0.597% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 88.069% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.201% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 89.21% |
| CellaVision AB (publ) | 928.71 Million SEK | 91.227% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -41.14% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -271.083% |
| C-Rad AB (publ) | 404 Million SEK | 79.833% |
| Duearity AB (publ) | 15.14 Million SEK | -437.989% |
| Dignitana AB (publ) | 44.83 Million SEK | -81.734% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 21.886% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.852% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 20.621% |
| Iconovo AB (publ) | 128.07 Million SEK | 36.389% |
| Integrum AB (publ) | 164.85 Million SEK | 50.58% |
| Luxbright AB (publ) | 40.68 Million SEK | -100.245% |
| Mentice AB (publ) | 322.52 Million SEK | 74.739% |
| OssDsign AB (publ) | 356.38 Million SEK | 77.139% |
| Paxman AB (publ) | 167.12 Million SEK | 51.25% |
| Promimic AB (publ) | 92.87 Million SEK | 12.277% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -108.659% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -26.641% |
| Sectra AB (publ) | 3.21 Billion SEK | 97.463% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 91.966% |
| Senzime AB (publ) | 433.54 Million SEK | 81.208% |
| SpectraCure AB (publ) | 144.83 Million SEK | 43.747% |
| Stille AB | 804.89 Million SEK | 89.878% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.503% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 96.289% |